ORGANOGENESIS HOLDINGS INC. Long-term Line of Credit
ORGANOGENESIS HOLDINGS INC. (ORGO) had Long-term Line of Credit of $0 as of 2023-09-30, per its 10-Q filed 2023-11-09.
Discontinued › Balance Sheet › Liabilities › Long-Term Debt, Unclassified
us-gaap:LineOfCredit · last filed 2023-11-09
- 2023-09-30: Long-term Line of Credit $0.00.
- 2023-06-30: Long-term Line of Credit $0.00.
- 2023-03-31: Long-term Line of Credit $0.00.
- 2022-12-31: Long-term Line of Credit $0.00.
| Period end | Long-term Line of Credit |
|---|---|
| 2023-09-30 | $0.00 10-Q · filed 2023-11-09 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-09 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-10 |
| 2022-12-31 | $0.00 10-Q · filed 2023-11-09 |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-09 |
| 2022-06-30 | $0.00 10-Q · filed 2022-08-09 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-10 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-01 |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-09 |
| 2020-12-31 | $10.00M 10-K · filed 2022-03-01 |
| 2019-06-30 | $33.48M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $30.98M 10-Q · filed 2019-05-10 |
| 2018-12-31 | $26.48M 10-Q · filed 2019-11-12 |
| 2017-12-31 | $17.62M 10-K · filed 2019-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |